A detailed history of Bank Of America Corp transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 243,112 shares of TARS stock, worth $12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243,112
Previous 229,492 5.93%
Holding current value
$12 Million
Previous $8.34 Million 20.8%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.17 - $38.73 $342,815 - $527,502
13,620 Added 5.93%
243,112 $6.61 Million
Q1 2024

May 15, 2024

SELL
$19.61 - $39.22 $182,980 - $365,961
-9,331 Reduced 3.91%
229,492 $8.34 Million
Q4 2023

Feb 14, 2024

BUY
$12.98 - $20.73 $1.48 Million - $2.37 Million
114,317 Added 91.82%
238,823 $4.84 Million
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $1.17 Million - $1.99 Million
101,547 Added 442.3%
124,506 $2.25 Million
Q1 2023

May 12, 2023

BUY
$11.92 - $16.27 $88,386 - $120,642
7,415 Added 47.7%
22,959 $288,000
Q4 2022

Feb 10, 2023

BUY
$14.12 - $18.72 $55,406 - $73,457
3,924 Added 33.77%
15,544 $227,000
Q3 2022

Nov 14, 2022

SELL
$14.08 - $18.5 $187,630 - $246,531
-13,326 Reduced 53.42%
11,620 $199,000
Q2 2022

Aug 12, 2022

BUY
$11.08 - $19.08 $204,392 - $351,968
18,447 Added 283.84%
24,946 $364,000
Q1 2022

May 16, 2022

SELL
$14.49 - $24.28 $60,321 - $101,077
-4,163 Reduced 39.05%
6,499 $109,000
Q4 2021

Feb 08, 2022

BUY
$21.21 - $29.68 $103,738 - $145,164
4,891 Added 84.75%
10,662 $240,000
Q3 2021

Nov 15, 2021

BUY
$21.45 - $29.22 $81,745 - $111,357
3,811 Added 194.44%
5,771 $125,000
Q2 2021

Sep 13, 2021

BUY
$27.16 - $38.59 $53,233 - $75,636
1,960 New
1,960 $57,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.32B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.